The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised its 2024 adjusted EBITDA loss guidance to $18 million-$16 million from its ...
Shares of Nevro Corp. NVRO gained 5% on Oct 13, following the announcement of the FDA approval for its spinal cord stimulation (SCS) system — Senza HFX iQ — for the treatment of chronic pain. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback